Furthermore, given previous evidence demonstrating that PEMF exposure modulates TRPC1 function (5), we examined whether TRPC1 expression level predicts breast cancer vulnerability to DOX and PEMF treatments. The gene discussed is TRPC1; the disease is breast carcinoma.